

# Sabina Signoretti

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4789648/sabina-signoretti-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

253  
papers

24,051  
citations

76  
h-index

153  
g-index

265  
ext. papers

28,698  
ext. citations

11.5  
avg, IF

6.25  
L-index

#	Paper	IF	Citations
253	Integrative clinical and molecular characterization of translocation renal cell carcinoma.. <i>Cell Reports</i> , <b>2022</b> , 38, 110190	10.6	3
252	Anti-CAIX BB[CAR4/8 T]cells exhibit superior efficacy in a ccRCC mouse model.. <i>Molecular Therapy - Oncolytics</i> , <b>2022</b> , 24, 385-399	6.4	2
251	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 569-569	2.2	
250	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 352-352	2.2	2
249	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100448	3.6	1
248	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 288-288	2.2	1
247	Sensitivity of mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2022</b> , 119, e2120403119 <sup>11.5</sup>	11.5	2
246	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , JCO2102938	2.2	2
245	Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 2868-2878	12.9	5
244	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS4596-TPS4596	2.2	1
243	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 649-661.e5	24.3	54
242	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. <i>Cancer Cell</i> , <b>2021</b> , 39, 632-648.e8	24.3	42
241	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4836-4847	12.9	6
240	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. <i>Cancer Immunology Research</i> , <b>2021</b> , 9, 156-169	12.5	20
239	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1371-1380	12.9	18
238	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 78-86	12.9	60
237	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	8

236	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. <i>Nature Communications</i> , <b>2021</b> , 12, 808	17.4	26
235	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , <b>2021</b> , 21, 904	4.8	3
234	Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. <i>Cancer Research</i> , <b>2021</b> ,	10.1	2
233	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial.. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
232	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
231	Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 1247-1255	13.4	51
230	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. <i>Nature Medicine</i> , <b>2020</b> , 26, 909-918	50.5	155
229	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. <i>Cancer Immunology Research</i> , <b>2020</b> , 8, 1075-1084	12.5	21
228	SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5002-5002	2.2	4
227	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5006-5006	2.2	26
226	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5010-5010	2.2	2
225	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5023-5023	2.2	6
224	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 5024-5024	2.2	8
223	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e19321-e19321	2.2	3
222	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 715-715	2.2	2
221	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS765-TPS765	2.2	1
220	Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 729-729	2.2	29
219	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 740-740	2.2	1

218	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, TPS5101-TPS5101	2.2	0
217	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 690-696	6.1	7
216	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 63-70	2.2	64
215	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 555-563	8.7	28
214	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma <b>2020</b> , 8,		8
213	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. <i>Nature Communications</i> , <b>2019</b> , 10, 4346	17.4	89
212	HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. <i>Science Signaling</i> , <b>2019</b> , 12,	8.8	25
211	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 2174-2184	12.9	47
210	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. <i>Science</i> , <b>2019</b> , 363, 1217-1222	33.3	165
209	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. <i>Nature Communications</i> , <b>2019</b> , 10, 1617	17.4	218
208	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. <i>Future Oncology</i> , <b>2019</b> , 15, 1683-1695	3.6	19
207	Editor@ Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 4194	12.9	
206	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. <i>Genes and Development</i> , <b>2019</b> , 33, 1718-1738	12.6	29
205	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 6080-6088	12.9	33
204	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 103-103	2.2	4
203	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4514-4514 <sup>2-2</sup>	2.2	5
202	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4568-4568	2.2	4
201	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4583-4583	2.2	8

200	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4597-TPS4597	2.2	3
199	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 548-548	2.2	19
198	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS684-TPS684	2.2	4
197	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4582-4582	2.2	
196	Cells Lacking the Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. <i>Cancer Discovery</i> , <b>2019</b> , 9, 230-247	24.4	67
195	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 1238-1242	8.7	25
194	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , <b>2018</b> , 23, 313-326.e5	10.6	295
193	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 206-218	36.3	153
192	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. <i>Nature Medicine</i> , <b>2018</b> , 24, 165-175	50.5	85
191	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , <b>2018</b> , 359, 801-806	33.3	562
190	Autochthonous tumors driven by loss have an ongoing requirement for the RBP2 histone demethylase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E3741-E3748	11.5	6
189	Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1. <i>Human Pathology: Case Reports</i> , <b>2018</b> , 11, 19-20	0.2	1
188	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 758-765	12.5	66
187	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. <i>Nature Genetics</i> , <b>2018</b> , 50, 1271-1281	36.3	249
186	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 619-619	2.2	2
185	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 626-626	2.2	0
184	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS710-TPS710	2.2	1
183	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 679-679	2.2	

182	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4597-TPS4597	2.2	
181	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. <i>Journal of Clinical Oncology</i> , <b>2018</b> , JCO2018792259	2.2	28
180	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. <i>PLoS Genetics</i> , <b>2018</b> , 14, e1007679	6	8
179	Loss of LDAH associated with prostate cancer and hearing loss. <i>Human Molecular Genetics</i> , <b>2018</b> , 27, 4194-4203	5.6	9
178	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2018</b> , 16, 341-348	3.3	4
177	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. <i>Oncologist</i> , <b>2017</b> , 22, 286-292	5.7	44
176	Renal cell carcinoma. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17009	51.1	963
175	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. <i>Cancer Discovery</i> , <b>2017</b> , 7, 750-765	24.4	77
174	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , <b>2017</b> , 72, 557-564	10.2	81
173	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. <i>Journal of Urology</i> , <b>2017</b> , 198, 817-823	2.5	21
172	Uncommon Tumors of the Kidney <b>2017</b> , 19-40		0
171	HIF activation causes synthetic lethality between the tumor suppressor and the histone methyltransferase. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	24
170	In Reply. <i>Oncologist</i> , <b>2017</b> , 22, 1561	5.7	
169	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2159-2168	12.9	7
168	p63+ ureteric bud tip cells are progenitors of intercalated cells. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	12
167	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4573-4573 <sup>1</sup>	2.2	
166	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS4596-TPS4596	2.2	7
165	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 477-477	2.2	7

164	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 513-513	2.2	1
163	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. <i>Oncotarget</i> , <b>2017</b> , 8, 103428-103436	3.3	13
162	Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 434-434	2.2	2
161	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4576-4576	2.2	
160	pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner. <i>Science</i> , <b>2016</b> , 353, 929-32	33.3	120
159	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. <i>Scientific Reports</i> , <b>2016</b> , 6, 27702	4.9	38
158	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , <b>2016</b> , 14, 820-4	7.3	26
157	Landscape of tumor-infiltrating T cell repertoire of human cancers. <i>Nature Genetics</i> , <b>2016</b> , 48, 725-32	36.3	193
156	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e585-e594	3.3	24
155	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2445-2452	12.9	150
154	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 135-45	59.2	753
153	Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, e25-36	3.3	34
152	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23221-e23221	2.2	1
151	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 485-485	2.2	1
150	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 501-501	2.2	1
149	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 545-545	2.2	8
148	Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation. <i>Oncotarget</i> , <b>2016</b> , 7, 29901-15	3.3	39
147	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. <i>Oncotarget</i> , <b>2016</b> , 7, 41857-41869	3.3	19

146	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 616-616	2.2	176
145	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 4535-4535	2.2	
144	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. <i>Oncotarget</i> , <b>2016</b> , 7, 34341-55	3.3	185
143	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. <i>PLoS Genetics</i> , <b>2016</b> , 12, e1006242	6	62
142	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. <i>Cell</i> , <b>2016</b> , 166, 126-39	5.2	131
141	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies. <i>Cancer</i> , <b>2016</b> , 122, 2389-98	6.4	9
140	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2016</b> , 14, 304-313.e6	3.3	10
139	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology Focus</i> , <b>2016</b> , 2, 633-639	5.1	9
138	On-target efficacy of a HIF-2 $\alpha$ antagonist in preclinical kidney cancer models. <i>Nature</i> , <b>2016</b> , 539, 107-111	50.4	249
137	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 3655-3663	2.2	111
136	Killer immunoglobulin-like receptor (KIR) and KIR-ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. <i>Cancer Immunology, Immunotherapy</i> , <b>2016</b> , 65, 1523-1532	7.4	4
135	RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma. <i>Molecular Cancer Research</i> , <b>2015</b> , 13, 130-7	6.6	32
134	The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 561-8	12.9	114
133	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1925-1934	12.9	48
132	Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1071-7	12.9	173
131	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , <b>2015</b> , 5, 1164-1177	24.4	581
130	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. <i>Molecular Cancer</i> , <b>2015</b> , 14, 119	42.1	35
129	Adult Renal Cell Carcinoma: A Review of Established Entities from Morphology to Molecular Genetics. <i>Surgical Pathology Clinics</i> , <b>2015</b> , 8, 587-621	3.9	32



128	miR-p63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. <i>Human Pathology</i> , <b>2015</b> , 46, 384-9	3.7	11
127	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. <i>Cancer</i> , <b>2015</b> , 121, 3435-43	6.4	53
126	Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. <i>Histopathology</i> , <b>2015</b> , 66, 901-4	7.3	19
125	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3. <i>Cancer Cytopathology</i> , <b>2015</b> , 123, 696-706	3.9	10
124	Cell kinetic studies fail to identify sequentially proliferating progenitors as the major source of epithelial renewal in the adult murine prostate. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128489	3.7	6
123	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study <b>2015</b> , 3, 3		63
122	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1158-64	12.5	205
121	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , <b>2015</b> , 3, 1308-15	12.5	96
120	Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. <i>Cancer Discovery</i> , <b>2015</b> , 5, 550-63	24.4	18
119	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4519-4519	2.2	1
118	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 405-405	2.2	1
117	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 408-408	2.2	2
116	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 422-422	2.2	1
115	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4560-4560	2.2	
114	A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. <i>EMBO Molecular Medicine</i> , <b>2014</b> , 6, 519-38	12	134
113	The somatic genomic landscape of chromophobe renal cell carcinoma. <i>Cancer Cell</i> , <b>2014</b> , 26, 319-330	24.3	521
112	Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. <i>Cancer Cell</i> , <b>2014</b> , 26, 222-34	24.3	51
111	D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. <i>Developmental Cell</i> , <b>2014</b> , 30, 255-67	10.2	22

110	Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. <i>Cell Metabolism</i> , <b>2014</b> , 19, 795-809	24.6	311
109	Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. <i>Cancer Discovery</i> , <b>2014</b> , 4, 546-53	24.4	224
108	Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 1889-94	2.2	177
107	Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 1531-40	7.5	25
106	Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. <i>Cancer Discovery</i> , <b>2014</b> , 4, 896-904	24.4	75
105	Identification of ALK gene alterations in urothelial carcinoma. <i>PLoS ONE</i> , <b>2014</b> , 9, e103325	3.7	8
104	Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. <i>Cancer Discovery</i> , <b>2014</b> , 4, 1140-53	24.4	361
103	Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 1873-83	12.9	38
102	MET as a target in papillary renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3361-3	12.9	18
101	GRK3 is essential for metastatic cells and promotes prostate tumor progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2014</b> , 111, 1521-6	11.5	30
100	Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. <i>Cell</i> , <b>2013</b> , 155, 844-57	56.2	117
99	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 81-7	21.7	46
98	SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. <i>Cancer Cell</i> , <b>2013</b> , 24, 738-50	24.3	111
97	Renal-cell carcinoma: a step closer to a new classification. <i>Lancet Oncology, The</i> , <b>2013</b> , 14, 105-7	21.7	7
96	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2013</b> , 31, 1788-93	2.8	37
95	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. <i>Nature Genetics</i> , <b>2013</b> , 45, 747-55	36.3	121
94	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. <i>Nature Genetics</i> , <b>2013</b> , 45, 739-746	36.3	100
93	The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 5218-26	12.9	65

92	Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. <i>Cancer Discovery</i> , <b>2013</b> , 3, 44-51	24.4	40
91	Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. <i>Cancer Research</i> , <b>2013</b> , 73, 2718-36	10.1	174
90	Identification of CDCP1 as a hypoxia-inducible factor 2 (HIF-2) target gene that is associated with survival in clear cell renal cell carcinoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 3483-8	11.5	48
89	p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2013</b> , 110, 8105-10	11.5	157
88	Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 370-370	2.2	1
87	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 260-260	2.2	
86	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 278-278	2.2	
85	Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 387-387	2.2	
84	The requirement for cyclin D function in tumor maintenance. <i>Cancer Cell</i> , <b>2012</b> , 22, 438-51	24.3	234
83	BRAF mutations in metanephric adenoma of the kidney. <i>European Urology</i> , <b>2012</b> , 62, 917-22	10.2	76
82	RET protein expression in papillary renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2012</b> , 30, 900-5	2.8	12
81	The glomuvenous malformation protein Glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7. <i>Molecular Cell</i> , <b>2012</b> , 46, 67-78	17.6	51
80	Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. <i>Cancer Discovery</i> , <b>2012</b> , 2, 1150-65	24.4	107
79	Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC <b>2012</b> , 69-89		
78	Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. <i>International Journal of Hyperthermia</i> , <b>2011</b> , 27, 527-38	3.7	44
77	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. <i>Nature Genetics</i> , <b>2011</b> , 43, 964-968	36.3	242
76	Genetic and functional studies implicate HIF1 as a 14q kidney cancer suppressor gene. <i>Cancer Discovery</i> , <b>2011</b> , 1, 222-35	24.4	283
75	Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. <i>PLoS ONE</i> , <b>2011</b> , 6, e19144	3.7	59

74	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. <i>Nature</i> , <b>2011</b> , 470, 269-73	50.4	383
73	Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. <i>Journal of Pathology</i> , <b>2011</b> , 225, 212-21	9.4	32
72	Pml represses tumour progression through inhibition of mTOR. <i>EMBO Molecular Medicine</i> , <b>2011</b> , 3, 249-57	15	
71	Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma. <i>Journal of Virology</i> , <b>2011</b> , 85, 5581-92	6.6	4
70	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2011</b> , 108, 13379-86	11.5	121
69	The landscape of somatic copy-number alteration across human cancers. <i>Nature</i> , <b>2010</b> , 463, 899-905	50.4	2590
68	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. <i>BJU International</i> , <b>2010</b> , 106, 772-8	5.6	73
67	The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 3628-38	12.9	165
66	Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. <i>Circulation</i> , <b>2010</b> , 122, 1004-16	16.7	102
65	Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. <i>American Journal of Clinical Pathology</i> , <b>2010</b> , 134, 873-9	1.9	82
64	Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. <i>Molecular Cancer Therapeutics</i> , <b>2010</b> , 9, 2793-802	6.1	57
63	Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. <i>Radiology</i> , <b>2010</b> , 255, 62-74	20.5	67
62	Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model?. <i>Radiology</i> , <b>2010</b> , 257, 685-96	20.5	43
61	A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 11002-7	11.5	54
60	FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. <i>Cancer Cell</i> , <b>2010</b> , 18, 472-84	24.3	112
59	LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 626-35	6.1	178
58	Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2009</b> , 101, 519-32	9.7	293
57	Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. <i>Cancer Research</i> , <b>2009</b> , 69, 4674-81	10.1	327

56	Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?. <i>Radiology</i> , <b>2009</b> , 251, 731-42	20.5	93
55	Reciprocal effects of STAT5 and STAT3 in breast cancer. <i>Molecular Cancer Research</i> , <b>2009</b> , 7, 966-76	6.6	107
54	Risk of bilateral renal cell cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3737-41	2.2	35
53	Treatment selection for patients with metastatic renal cell carcinoma. <i>Cancer</i> , <b>2009</b> , 115, 2327-33	6.4	27
52	Tissue biomarkers in renal cell carcinoma: issues and solutions. <i>Cancer</i> , <b>2009</b> , 115, 2290-7	6.4	31
51	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. <i>Clinical Proteomics</i> , <b>2009</b> , 5, 37-45	5	6
50	p63 promotes cell survival through fatty acid synthase. <i>PLoS ONE</i> , <b>2009</b> , 4, e5877	3.7	20
49	Adult Prostate Epithelium Renewal, Stem Cells and Cancer <b>2009</b> , 231-246		
48	Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. <i>Nature</i> , <b>2008</b> , 454, 776-9	50.4	599
47	VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. <i>Nature Cell Biology</i> , <b>2008</b> , 10, 361-9	23.4	198
46	Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. <i>BJU International</i> , <b>2008</b> , 101 Suppl 4, 31-5	5.6	12
45	A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. <i>Cancer Cell</i> , <b>2008</b> , 14, 146-55	24.3	136
44	Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. <i>American Journal of Roentgenology</i> , <b>2008</b> , 191, 133-9	5.4	61
43	Tissue-based research in kidney cancer: current challenges and future directions. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3699-705	12.9	20
42	p63 in prostate biology and pathology. <i>Journal of Cellular Biochemistry</i> , <b>2008</b> , 103, 1354-68	4.7	58
41	Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , <b>2007</b> , 5, 379-85	3.3	156
40	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , <b>2007</b> , 39, 347-51	36.3	847
39	Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. <i>Journal of Investigative Dermatology</i> , <b>2007</b> , 127, 106-15	4.3	18

38	Prostate stem cells: from development to cancer. <i>Seminars in Cancer Biology</i> , <b>2007</b> , 17, 219-24	12.7	30
37	Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. <i>Radiology</i> , <b>2007</b> , 244, 464-70	20.5	65
36	The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 758s-763s	12.9	86
35	Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. <i>Radiology</i> , <b>2006</b> , 240, 82-9	20.5	42
34	Androgen-dependent regulation of Her-2/neu in prostate cancer cells. <i>Cancer Research</i> , <b>2006</b> , 66, 5723-8	10.1	66
33	Defining cell lineages in the prostate epithelium. <i>Cell Cycle</i> , <b>2006</b> , 5, 138-41	4.7	40
32	A working group classification of focal prostate atrophy lesions. <i>American Journal of Surgical Pathology</i> , <b>2006</b> , 30, 1281-91	6.7	97
31	Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. <i>Cancer Research</i> , <b>2005</b> , 65, 3044-8	10.1	668
30	Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3714-21	12.9	358
29	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 10238-43	11.5	39
28	Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. <i>Radiology</i> , <b>2005</b> , 235, 469-77	20.5	76
27	p63 regulates commitment to the prostate cell lineage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 11355-60	11.5	120
26	Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. <i>Radiology</i> , <b>2005</b> , 235, 81-8	20.5	50
25	Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. <i>Cancer Research</i> , <b>2004</b> , 64, 8867-75	10.1	153
24	Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27. <i>Journal of Cutaneous Pathology</i> , <b>2004</b> , 31, 477-82	1.7	17
23	The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. <i>Cancer Cell</i> , <b>2004</b> , 5, 253-61	24.3	269
22	Intermediate basal cells of the prostate: in vitro and in vivo characterization. <i>Prostate</i> , <b>2003</b> , 55, 206-18	4.2	81
21	Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. <i>Oncogene</i> , <b>2002</b> , 21, 4099-107	9.2	92

20	Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. <i>Nature</i> , <b>2002</b> , 419, 162-7	50.4	356
19	Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. <i>Modern Pathology</i> , <b>2002</b> , 15, 1302-8	9.8	99
18	Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. <i>Molecular and Cellular Biology</i> , <b>2002</b> , 22, 635-43	4.8	65
17	Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection. <i>Diagnostic Molecular Pathology</i> , <b>2002</b> , 11, 187-92		19
16	Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. <i>Journal of Clinical Investigation</i> , <b>2002</b> , 110, 633-41	15.9	106
15	Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. <i>Cancer Research</i> , <b>2002</b> , 62, 89-98	10.1	86
14	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman disease. <i>Journal of Pathology</i> , <b>2001</b> , 193, 200-9	9.4	41
13	Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. <i>Molecular Endocrinology</i> , <b>2001</b> , 15, 765-82		70
12	Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. <i>Modern Pathology</i> , <b>2001</b> , 14, 437-42	9.8	53
11	Estrogen receptor beta in prostate cancer: brake pedal or accelerator?. <i>American Journal of Pathology</i> , <b>2001</b> , 159, 13-6	5.8	68
10	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman disease <b>2001</b> , 193, 200		3
9	Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. <i>Journal of Cutaneous Pathology</i> , <b>2000</b> , 27, 228-34	1.7	45
8	Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. <i>Molecular and Cellular Biology</i> , <b>2000</b> , 20, 8969-82	4.8	496
7	BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. <i>Journal of Biological Chemistry</i> , <b>2000</b> , 275, 39223-30	5.4	166
6	p63 is a prostate basal cell marker and is required for prostate development. <i>American Journal of Pathology</i> , <b>2000</b> , 157, 1769-75	5.8	470
5	Role of the Cdc25A phosphatase in human breast cancer. <i>Journal of Clinical Investigation</i> , <b>2000</b> , 106, 753-61	15.9	159
4	Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. <i>American Journal of Pathology</i> , <b>1999</b> , 154, 67-75	5.8	73
3	Melanocytic nevi of palms and soles: a histological study according to the plane of section. <i>American Journal of Surgical Pathology</i> , <b>1999</b> , 23, 283-7	6.7	44

2	Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. <i>American Journal of Surgical Pathology</i> , <b>1997</b> , 21, 1307-15	6.7	206
1	Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma		2